<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601625</url>
  </required_header>
  <id_info>
    <org_study_id>D3461C00006</org_study_id>
    <nct_id>NCT02601625</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects</brief_title>
  <official_title>A Randomized, Phase 1, Placebo-controlled, Double-blind, Single-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Subcutaneously and Intravenously Delivered Anifrolumab in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, Randomized, Placebo-Controlled, Double-Blind Study to Assess the
      Pharmacokinetics and Safety of anifrolumab following Single-Dose administration to healthy
      subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I placebo-controlled study to assess the pharmacokinetics, safety and
      tolerability of 2 doses of anifrolumab via the subcutaneous (SC) route of administration and
      1 dose of anifrolumab via intravenous (IV) route in healthy subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Observed maximum serum concentration (Cmax) following single dose of anifrolumab</measure>
    <time_frame>On Day 1 pre-dose and at 5 minutes (IV cohort only), 24 and 48 hours post-dose and at each follow-up visit, up to 85 days</time_frame>
    <description>Estimation of Cmax of anifrolumab,up to 13 samples collected in total</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum concentration-time curve from time zero to time of last quantifiable concentration (AUC0-t) following single dose of anifrolumab</measure>
    <time_frame>On Day 1 pre-dose and at 5 minutes (IV cohort only), 24 and 48 hours post-dose and at each follow-up visit, up to 85 days</time_frame>
    <description>Estimation of AUC(0-t) of anifrolumab, up to 13 samples collected in total</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under serum concentration-time curve from time zero extrapolated to infinity(AUCinf) following single dose of anifrolumab</measure>
    <time_frame>On Day 1 pre-dose and at 5 minutes (IV cohort only), 24 and 48 hours post-dose and at each follow-up visit, up to 85 days</time_frame>
    <description>Estimation of AUCinf of anifrolumab, up to 13 samples collected in total</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of anifrolumab by assessment of the number of adverse events and the number of subjects with adverse events</measure>
    <time_frame>From screening to final follow-up visit, up to 16 weeks</time_frame>
    <description>To assess the safety and tolerability of single doses of anifrolumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of anifrolumab by assessment of blood pressure</measure>
    <time_frame>From screening to final follow-up visit, up to 16 weeks</time_frame>
    <description>To assess the safety and tolerability of single doses of anifrolumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of anifrolumab by assessment of pulse</measure>
    <time_frame>From screening to final follow-up visit, up to 16 weeks</time_frame>
    <description>To assess the safety and tolerability of single doses of anifrolumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of anifrolumab by assessment of body temperature</measure>
    <time_frame>From screening to final follow-up visit, up to 16 weeks</time_frame>
    <description>To assess the safety and tolerability of single doses of anifrolumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of anifrolumab by assessment of electrocardigram (ECG)</measure>
    <time_frame>From screening to final follow-up visit, up to 16 weeks</time_frame>
    <description>To assess the safety and tolerability of single doses of anifrolumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of anifrolumab by assessment of physical examination</measure>
    <time_frame>From screening to final follow-up visit, up to 16 weeks</time_frame>
    <description>Including the general appearance, skin, cardiovascular, respiratory, abdomen, head and neck (including ears, eyes, nose and throat), lymph nodes, thyroid, musculoskeletal and neurological systems</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of anifrolumab by assessment of safety laboratory tests</measure>
    <time_frame>From screening to final follow-up visit, up to 16 weeks</time_frame>
    <description>This is a composite of clinical chemistry, hematology and urinalysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of anifrolumab by assessment of local injection site pain (SC cohorts)</measure>
    <time_frame>After dosing on Day 1 until 48 hours post-dose</time_frame>
    <description>A scale rating of 0-100 for injection-site assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of anifrolumab by assessment of local injection site pruritus (SC cohorts)</measure>
    <time_frame>After dosing on Day 1 until 48 hours post-dose</time_frame>
    <description>A scale rating of 0-100 for injection-site assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety and tolerability of anifrolumab by assessment of local injection site reaction (SC cohorts)</measure>
    <time_frame>After dosing on Day 1 until 48 hours post-dose</time_frame>
    <description>Local injection site reactions (including erythema and induration)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of anifrolumab delivered as an IV infusion by the measurement of anti-drug antibody (ADA)</measure>
    <time_frame>Pre-dose and at 3 follow-up Visit, up to 85 days</time_frame>
    <description>Up to 4 samples collected in total</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of anifrolumab delivered as a SC injection by the measurement of anti-drug antibody (ADA)</measure>
    <time_frame>Pre-dose and at 3 follow-up Visit, up to 85 days</time_frame>
    <description>Up to 4 samples collected in total</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Safety</condition>
  <condition>Pharmacokinetics</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Anifrolumab 300 mg SC injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg single dose anifrolumab delivered as 2 separate 1 mL SC injections administered serially</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anifrolumab 300 mg IV infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg single dose anifrolumab delivered as an IV infusion over 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anifrolumab 600 mg SC infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg single dose anifrolumab or placebo delivered as 4 mL SC by infusion pump</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 300 mg SC injections</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>300 mg single dose placebo delivered as 2 separate 1 mL SC injections administered serially</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 300 mg IV infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>300 mg single dose placebo delivered as an IV infusion over 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 600mg SC infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>600 mg single dose placebo delivered as 4 mL SC by infusion pump</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anifrolumab SC injection (300mg)</intervention_name>
    <description>300 mg of anifrolumab delivered as 2 separate 1 mL SC injections administered serially on Day 1</description>
    <arm_group_label>Anifrolumab 300 mg SC injections</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anifrolumab IV infusion (300mg)</intervention_name>
    <description>300 mg of anifrolumab delivered as an IV infusion over 30 minutes on Day 1</description>
    <arm_group_label>Anifrolumab 300 mg IV infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anifrolumab SC infusion (600mg)</intervention_name>
    <description>600 mg of anifrolumab delivered as 4 mL SC by infusion pump on Day 1</description>
    <arm_group_label>Anifrolumab 600 mg SC infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anifrolumab placebo SC injection (300mg)</intervention_name>
    <description>300mg of placebo delivered as 2 separate 1 mL SC injections administered serially on Day 1</description>
    <arm_group_label>Placebo 300 mg SC injections</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anifrolumab placebo IV infusion (300mg)</intervention_name>
    <description>600mg of placebo delivered as an IV infusion over 30 minutes on Day 1</description>
    <arm_group_label>Placebo 300 mg IV infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anifrolumab placebo SC infusion (600mg)</intervention_name>
    <description>600 mg of placebo delivered as 4 mL SC by infusion pump on Day 1</description>
    <arm_group_label>Placebo 600mg SC infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed and dated, written informed consent prior to any study specific
             procedures.

          2. Healthy male and/or female subjects aged 18 - 55 years.

          3. Females must have a negative pregnancy test at screening.

          4. Females with an intact cervix must have documentation of a Pap smear with no
             documented malignancy.

          5. Have a body mass index (BMI) between 18 and 32 kg/m2, inclusive, and weigh at least 50
             kg.

          6. Must have adequate abdominal adipose tissue for SC injection.

          7. No history of latent or active TB prior to screening.

          8. A chest radiograph with no evidence of current active infection or old active TB,
             malignancy, or clinically significant abnormalities within 6 months prior to
             screening.

        Exclusion Criteria:

          1. History of any clinically significant disease or disorder which may put the subject at
             risk .

          2. History or presence of hepatic or renal disease.

          3. Any clinically significant illness, medical/surgical procedure, or trauma within 8
             weeks of participation .

          4. Any clinically significant chronic or recent infection requiring hospitalization or
             treatment with anti-infectives.

          5. History of cancer, apart from squamous or basal cell carcinoma of the skin.

          6. Any clinically significant lab, vital sign or ECG abnormalities as judged by the
             investigator.

          7. Known history of a primary immunodeficiency,HIV splenectomy or an underlying
             condition.

          8. Any positive result on screening for hepatitis B, hepatitis C or HIV antibody.

          9. History of drug abuse within 1 year of participation.

         10. Has received another new chemical entity (defined as a compound which has not been
             approved for marketing) within 4 weeks or 5 half-lives prior to participation.

         11. Previous receipt of:

               -  Anifrolumab;

               -  B cell-depleting therapy (including but not limited to epratuzumab, ocrelizumab,
                  or rituximab) ≤ 52 weeks prior to screening.

         12. History of allergy/hypersensitivity to drugs with a similar chemical structure or
             class to anifrolumab or to any human gamma globulin therapy.

         13. Any live or attenuated vaccine within 8 weeks prior to participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Goldwater, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PAREXEL Early Phase Clinical Unit, Baltimore, United States of America</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2015</study_first_submitted>
  <study_first_submitted_qc>November 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2015</study_first_posted>
  <last_update_submitted>June 9, 2016</last_update_submitted>
  <last_update_submitted_qc>June 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tolerability</keyword>
  <keyword>Anifrolumab</keyword>
  <keyword>Subcutaneous injection</keyword>
  <keyword>Intravenous infusion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 23, 2017</submitted>
    <returned>October 13, 2017</returned>
    <submitted>December 7, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

